Disease-specific quality of life evaluation and its determinants in Cushing's syndrome: what have we learnt?

Pituitary · 2014 · PMC3942630 · PMID 23564339

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Analysis of data from the pasireotide clinical trial showed a clear trend, after 12 months of treatment, to differences in CushingQoL scores between patients with fully controlled mean UFC [58.0 (3.7)] and those with uncontrolled UFC [51.5 (3.4)], though the differences were not statistically significant.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.